MX2016009653A - Anticuerpos contra glicoproteina f de virus hendra y nipah. - Google Patents

Anticuerpos contra glicoproteina f de virus hendra y nipah.

Info

Publication number
MX2016009653A
MX2016009653A MX2016009653A MX2016009653A MX2016009653A MX 2016009653 A MX2016009653 A MX 2016009653A MX 2016009653 A MX2016009653 A MX 2016009653A MX 2016009653 A MX2016009653 A MX 2016009653A MX 2016009653 A MX2016009653 A MX 2016009653A
Authority
MX
Mexico
Prior art keywords
antibodies
hendra
fragments
glycoprotein
antibodies against
Prior art date
Application number
MX2016009653A
Other languages
English (en)
Inventor
C Yee-Peng Chan
Broder Christopher
Original Assignee
Henry M Jackson Found Advancement Military Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry M Jackson Found Advancement Military Medicine Inc filed Critical Henry M Jackson Found Advancement Military Medicine Inc
Publication of MX2016009653A publication Critical patent/MX2016009653A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a anticuerpos o fragmentos de anticuerpos que se unen, neutralizan y/o inhiben los virus Hendra o Nipah. La invención proporciona anticuerpos o fragmentos de anticuerpos que se unen selectivamente a la glicoproteína F del virus Hendra o Nipah, y composiciones farmacéuticas que incluyen los anticuerpos y/o fragmentos. La invención además proporciona polinucleótidos que codifican los anticuerpos y fragmentos de la invención y células hospedadoras transformadas con ellos. Adicionalmente, la invención describe métodos profilácticos, terapéuticos y de diagnóstico que emplean los anticuerpos, fragmentos, polinucleótidos y/o composiciones de la invención.
MX2016009653A 2014-01-24 2015-01-23 Anticuerpos contra glicoproteina f de virus hendra y nipah. MX2016009653A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461931006P 2014-01-24 2014-01-24
PCT/US2015/012641 WO2015112836A2 (en) 2014-01-24 2015-01-23 Antibodies against f glycoprotein of hendra and nipah viruses

Publications (1)

Publication Number Publication Date
MX2016009653A true MX2016009653A (es) 2017-03-27

Family

ID=53682129

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009653A MX2016009653A (es) 2014-01-24 2015-01-23 Anticuerpos contra glicoproteina f de virus hendra y nipah.

Country Status (14)

Country Link
US (3) US9982038B2 (es)
EP (1) EP3096789B1 (es)
JP (1) JP2017505124A (es)
KR (1) KR20160127736A (es)
CN (1) CN106163560A (es)
AU (1) AU2015209171B2 (es)
BR (1) BR112016017046A2 (es)
CA (1) CA2937866A1 (es)
CL (1) CL2016001886A1 (es)
ES (1) ES2843543T3 (es)
MX (1) MX2016009653A (es)
PH (1) PH12016501444A1 (es)
RU (1) RU2016134256A (es)
WO (1) WO2015112836A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016009653A (es) * 2014-01-24 2017-03-27 Henry M Jackson Found Advancement Military Medicine Inc Anticuerpos contra glicoproteina f de virus hendra y nipah.
CN108250290B (zh) * 2018-02-23 2024-03-12 上海捌加壹医药科技有限公司 Ccr4的n端重组蛋白及其用途
EP3829631A1 (en) 2018-08-03 2021-06-09 The United States of America, as represented by The Secretary, Department of Health and Human Services Nipah virus immunogens and their use
AU2020382653A1 (en) * 2019-11-12 2022-06-02 Vanderbilt University Human Hendra virus and Nipah virus antibodies and methods of use therefor
KR102264873B1 (ko) * 2020-01-17 2021-06-14 대한민국(질병관리청장) 니파바이러스 g 당단백질에 특이적인 단클론 항체 및 이의 용도
CN113968908B (zh) * 2020-07-22 2023-03-14 中国人民解放军军事科学院军事医学研究院 具有广谱中和活性的抗亨尼帕病毒单克隆抗体及应用
WO2023109844A1 (en) * 2021-12-14 2023-06-22 Doma Biopharmaceutical (Suzhou) Co., Ltd. Antibodies and uses thereof
CN117487005B (zh) * 2023-12-13 2024-03-08 中国人民解放军军事科学院军事医学研究院 靶向亨尼帕病毒融合蛋白diii区的广谱中和抗体及应用
US20250206808A1 (en) * 2023-12-22 2025-06-26 Mapp Biopharmaceutical, Inc. Antibodies Against Henipaviruses
WO2025264562A1 (en) * 2024-06-21 2025-12-26 Icahn School Of Medicine At Mount Sinai Henipavirus neutralizing monoclonal antibodies
WO2025265116A1 (en) * 2024-06-21 2025-12-26 Georgia State University Research Foundation, Inc. Nanobodies to henipavirus and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US7122185B2 (en) * 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
DE602005027258D1 (de) * 2005-03-14 2011-05-12 Us Gov Health & Human Serv Humane monoklonale antikörper gegen hendra- und nipah-viren
WO2008115296A2 (en) * 2006-11-21 2008-09-25 University Of Rochester Modified phage for displaying post-translationally modified proteins and uses thereof
EP3118213A1 (en) 2007-12-19 2017-01-18 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Soluble forms of hendra and nipah virus f glycoprotein and uses thereof
CN101952317B (zh) * 2008-01-24 2015-07-22 诺沃-诺迪斯克有限公司 人化抗-人nkg2a单克隆抗体
TWI412375B (zh) 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體
US20160272697A2 (en) * 2011-04-28 2016-09-22 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Neutralizing Antibodies to Nipah and Hendra Virus
US10202452B2 (en) 2012-04-20 2019-02-12 Aptevo Research And Development Llc CD3 binding polypeptides
MX2016009653A (es) * 2014-01-24 2017-03-27 Henry M Jackson Found Advancement Military Medicine Inc Anticuerpos contra glicoproteina f de virus hendra y nipah.

Also Published As

Publication number Publication date
US9982038B2 (en) 2018-05-29
BR112016017046A2 (pt) 2017-10-03
CL2016001886A1 (es) 2017-06-09
EP3096789B1 (en) 2020-10-28
KR20160127736A (ko) 2016-11-04
ES2843543T3 (es) 2021-07-19
RU2016134256A (ru) 2018-03-05
EP3096789A4 (en) 2017-07-26
US20210188950A1 (en) 2021-06-24
EP3096789A2 (en) 2016-11-30
WO2015112836A2 (en) 2015-07-30
AU2015209171B2 (en) 2020-08-06
PH12016501444A1 (en) 2016-08-22
AU2015209171A1 (en) 2016-09-01
US20160347827A1 (en) 2016-12-01
US10738104B2 (en) 2020-08-11
CN106163560A (zh) 2016-11-23
US11332517B2 (en) 2022-05-17
JP2017505124A (ja) 2017-02-16
US20180298081A1 (en) 2018-10-18
WO2015112836A3 (en) 2015-10-29
CA2937866A1 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
MX2016009653A (es) Anticuerpos contra glicoproteina f de virus hendra y nipah.
JOP20200192A1 (ar) أجسام مضادة لـ tigit
CY1121893T1 (el) Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων
CY1122510T1 (el) Μορια αντισωματος σε lag-3 και χρησεις αυτων
CO2018005614A2 (es) Anticuerpos que se unen específicamente a pd-1 y sus usos
CL2019002196A1 (es) Anticuerpos humanos neutralizantes que se unen a hemaglutinina de influenza a. (divisional solicitud 201701610)
ECSP18033227A (es) Anticuerpos agonistas que se unen específicamente a CD40 humana y métodos de uso
MX2024006564A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
MX2022005202A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
EA202092435A3 (ru) Моноклональные антитела против bcma
MX389663B (es) Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
CU24498B1 (es) Anticuerpos de factor xi
EA201691488A1 (ru) Молекулы антител против pd-1 и их применения
MX392098B (es) Anticuerpos neutralizantes de poliomavirus.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
MX389447B (es) Composiciones y métodos para anticuerpos dirigidos a bmp6.
UY36187A (es) Anticuerpos antagonistas de interferón alfa y omega
GT201800034A (es) Anticuerpos anti-cd154 y métodos de uso de estos
CR20170518A (es) Neutralización del virus chikungunya mediada por anticuerpos.
EP3379941A4 (en) BEVERAGE ANOEMULSIONS PRODUCED BY HIGH GRADE PROCEDURE
MX392761B (es) Anticuerpos anti-influenza b neutralizantes y usos de los mismos.
WO2014152946A3 (en) Polypeptides for treating and/or limiting influenza infection
EP3512877C0 (en) NIDOGEN-1 FRAGMENTS TEST